Chemical Biology and Drug Design
JULY 26, 2023
Exosome engineering can be conducted through surface and content modification of biological exosomes. In preisolation method, parental cells are stimulated to express some special genes like lncRNAs, miRNAs, and receptors to have the capacity to bind to the target cells and deliver their content.
Drug Discovery World
APRIL 5, 2023
Italian research institute and contract research organisation IRBM has become the only company from outside the United States to join cancer drug discovery network the Chemical Biology Consortium (CBC).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JULY 11, 2023
NK:IO is based on discoveries in natural killer (NK) cell biology from Hugh Brady, Professor of Immunology, and Matt Fuchter, Professor of Chemistry, at Imperial College. NK:IO’s platform activates blood stem cell progenitors to yield NK cell tumour-killing potency and very high yield cell production.
BMG Labtech
JANUARY 23, 2024
Our knowledge of the deep-sea, the largest biome on Earth, is in its infancy. Water covers more than 70% of the planet and the deep-sea accounts for more than 300 million km 2 of the Earth’s surface. 1,2 Scientists have only scratched the surface of life in the ocean depths but there are intriguing benefits to studying its organisms and ecosystems.
Drug Discovery World
AUGUST 5, 2022
Evonetix is reimaging biology by developing a different approach to gene synthesis. After some calculations on a whiteboard, I realised that it is controllable and within the laws of physics – it was just an engineering challenge. He holds a PhD and MEng in Electronic Engineering, both from Loughborough University.
Broad Institute
DECEMBER 13, 2023
Hung Group, Infectious Disease and Microbiome Program Michael Bogaev Princeton University Molecular Biology (major), B.A., Spanish (minor) Genetic Pertubation Platform (GPP) Mohammed Mutaher Harvard University Human Developmental and Regenerative Biology (major), B.A., Manguso Lab, TIDE Gili Schor Brown University Biology (major), B.A.,
Drug Target Review
JUNE 7, 2024
Unlike existing immunotherapies that are designed to “remove the brakes” from exhausted, pre-existing tumour-specific T cells, the ImmTAC platform can redirect any T cell in the patient’s body to recognise and kill tumour cells expressing the target of interest the ImmTAC was engineered for.
Expert insights. Personalized for you.
100 
Let's personalize your content